Glycated haemoglobin, HOMA2‐B , C‐peptide to glucose ratio and type 2 diabetes clusters as predictors for therapy failure in individuals with type 2 diabetes without insulin therapy: A registry analysis
Authors' conclusion
HbA1c, indices of insulin secretion capacity (HOMA2-B and CGR) and T2D clusters might be applicable tools to guide practitioners in the decision of whether insulin is required in people already diagnosed with T2D. These findings need to be validated in prospective studies.
Study context
- Population
- Individuals with T2D without previous insulin therapy; 41% female, median age 50 (IQR: 53–69) years, diabetes duration 9 (5–15) years; severe autoimmune diabetes cluster excluded
- Participants
- 159 individuals
- Exposure
- HbA1c, HOMA2-B, CGR and T2D clusters as predictors of therapy failure
- Outcome
- Composite glycaemic therapy failure:
- HbA1c increasing or remaining >8.0% (64 mmol/mol) 3 months after baseline on non-insulin agents
- Insulin initiation
- Hospital admission for acute hyperglycaemic events
- Follow-up
- Median observation of 57 months
Methodological detailsprospective cohort, prospective evaluation
- Prospective cohort
- Prospective evaluation
Main finding
As reported in the abstract
Composite primary endpoint (therapy failure)
Hazard ratio (95% CI)
MODhighest probability of primary endpoint
3.28(1.75–6.2)
SIDD
2.03(1.1–3.7)
Observational data: associations, not effects.
Further findings
| Outcome | HbA1c at baseline | HOMA2-B | CGR |
|---|---|---|---|
| Prediction of therapy failure (AUC) | |||
| AUC | 0.77 | 0.69 | 0.64 |
- Prediction of therapy failure (AUC): HbA1c best performance
Original publication
Glycated haemoglobin, HOMA2‐B , C‐peptide to glucose ratio and type 2 diabetes clusters as predictors for therapy failure in individuals with type 2 diabetes without insulin therapy: A registry analysis. Diabetes Obes Metab. Published 27 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →